lansoprazole has been researched along with Supranuclear Palsy, Progressive in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fawaz, MV | 1 |
Brooks, AF | 1 |
Rodnick, ME | 1 |
Carpenter, GM | 1 |
Shao, X | 1 |
Desmond, TJ | 1 |
Sherman, P | 1 |
Quesada, CA | 1 |
Hockley, BG | 1 |
Kilbourn, MR | 1 |
Albin, RL | 1 |
Frey, KA | 1 |
Scott, PJ | 1 |
1 other study available for lansoprazole and Supranuclear Palsy, Progressive
Article | Year |
---|---|
High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autoradiography; Brain; Carbon Radioisotopes; Dru | 2014 |